NuCana (NASDAQ:NCNA) Trading Down 0.5% – Here’s Why

NuCana PLC Sponsored ADR (NASDAQ:NCNA) shares were down 0.5% during mid-day trading on Thursday . The stock traded as low as $2.01 and last traded at $2.02. Approximately 41,854 shares were traded during mid-day trading, a decline of 3% from the average daily volume of 43,071 shares. The stock had previously closed at $2.03.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NuCana in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, NuCana currently has an average rating of “Sell”.

NuCana Price Performance

The stock has a market capitalization of $8.40 million, a price-to-earnings ratio of -0.68 and a beta of 2.18. The business’s 50-day simple moving average is $1.99 and its two-hundred day simple moving average is $2.61.

NuCana (NASDAQ:NCNA) last announced its quarterly earnings results on Friday, May 15th. The company reported ($1.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.64) by $1.39.

Institutional Inflows and Outflows

An institutional investor recently raised its position in NuCana stock. FNY Investment Advisers LLC lifted its position in shares of NuCana PLC Sponsored ADR (NASDAQ:NCNA) by 210.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,000 shares of the company’s stock after purchasing an additional 6,774 shares during the period. FNY Investment Advisers LLC owned about 33.33% of NuCana worth $36,000 as of its most recent SEC filing. 44.00% of the stock is currently owned by hedge funds and other institutional investors.

NuCana Company Profile

NuCana plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure.